MedTrace Logo

Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients

NCT02338115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-05-02

No results posted yet for this study

Summary

The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.

Conditions

Interventions

DRUG

Paclitaxel 80mg/m2 weekly x 12 weeks

Sponsors & Collaborators

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Daniel L Hertz, PharmD, PhD · University of Michigan

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-12-20
Completion
2016-12-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338115 on ClinicalTrials.gov